43 FY 2013 Drug GMP Warning Letters Hit Data Integrity, Training and More
This article was originally published in The Gold Sheet
FDA’s 43 fiscal year 2013 drug GMP warning letters highlighted problems related to data integrity, inadequate testing of raw materials and inadequate employee training. These trends were associated with increases in warning letters to manufacturers in India and to U.S.-based compounding pharmacies.
You may also be interested in...
More unannounced inspections abroad would warm Senate Finance Committee chairman to President Trump's drug importation plan.
FDA investigators are continuing to find contamination problems and inadequate testing, according to 20 warning letters issued in the first half of 2013, as well as a troubling trend of repeat observations at Baxter, Hospira and Apotex. Observers say to expect more sterility concerns in future warning letters, particularly involving mold, as FDA ramps up GMP enforcement at compounding pharmacies.
Action responds to methanol contamination in hand sanitizers manufactured in Mexico and marketed in the US under numerous brands that followed a loosening standards for the products to drive a swift increase in production and meet surging demand during the coronavirus pandemic.